X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atrasentan (86) 86
male (55) 55
humans (50) 50
animals (41) 41
index medicus (39) 39
pyrrolidines - pharmacology (36) 36
endothelin (32) 32
endothelin receptor antagonists (27) 27
pyrrolidines - administration & dosage (26) 26
middle aged (22) 22
prostate cancer (21) 21
oncology (20) 20
pharmacology & pharmacy (20) 20
aged (19) 19
endothelin a receptor antagonists (19) 19
rats (19) 19
female (18) 18
blood pressure - drug effects (17) 17
prostatic neoplasms - drug therapy (17) 17
pyrrolidines - therapeutic use (15) 15
dose-response relationship, drug (14) 14
treatment outcome (14) 14
antagonist (13) 13
endothelin-1 (13) 13
expression (13) 13
pyrrolidines - adverse effects (13) 13
receptor, endothelin a (13) 13
docetaxel (12) 12
endothelin-1 - metabolism (12) 12
peripheral vascular disease (12) 12
prostatic neoplasms - pathology (12) 12
administration, oral (11) 11
antimitotic agents (11) 11
antineoplastic agents (11) 11
men (11) 11
pharmacokinetics (11) 11
rats, sprague-dawley (11) 11
research (11) 11
antineoplastic agents - therapeutic use (10) 10
cancer (10) 10
cardiac & cardiovascular systems (10) 10
care and treatment (10) 10
aged, 80 and over (9) 9
blockade (9) 9
bosentan (9) 9
double-blind method (9) 9
mice (9) 9
pyrrolidines - pharmacokinetics (9) 9
refractory prostate-cancer (9) 9
safety (9) 9
urology & nephrology (9) 9
adult (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cells (8) 8
chemotherapy (8) 8
clinical trials (8) 8
controlled-trial (8) 8
endothelin receptor (8) 8
hemodynamics (8) 8
hypertension - physiopathology (8) 8
progression (8) 8
time factors (8) 8
analysis (7) 7
bone neoplasms - secondary (7) 7
dosage and administration (7) 7
endothelin b receptor antagonists (7) 7
kidney - drug effects (7) 7
pain (7) 7
prostatic neoplasms - mortality (7) 7
receptor antagonist (7) 7
receptor, endothelin a - metabolism (7) 7
antineoplastic agents - administration & dosage (6) 6
blood-pressure (6) 6
bone neoplasms - drug therapy (6) 6
clinical trials as topic (6) 6
diabetic nephropathy (6) 6
disease-free survival (6) 6
dogs (6) 6
endothelin-1 - antagonists & inhibitors (6) 6
endothelin-receptor antagonist (6) 6
growth-factor (6) 6
health aspects (6) 6
hemodynamics - drug effects (6) 6
hypertension - chemically induced (6) 6
mitoxantrone plus prednisone (6) 6
orchiectomy (6) 6
receptors, endothelin - physiology (6) 6
survival (6) 6
vasoconstriction (6) 6
vasoconstriction - drug effects (6) 6
antineoplastic agents - pharmacology (5) 5
article (5) 5
castration-resistant prostate cancer (5) 5
disease progression (5) 5
drug resistance, neoplasm (5) 5
drug therapy (5) 5
efficacy (5) 5
endothelin-1 - blood (5) 5
et receptors (5) 5
heart failure - drug therapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 09/2010, Volume 122, Issue 10, pp. 958 - 966
Background-Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was... 
coronary disease | endothelin | endothelium | blood flow | CONTROLLED-TRIAL | CARDIAC & CARDIOVASCULAR SYSTEMS | EXPERIMENTAL HYPERCHOLESTEROLEMIA | ENDOGENOUS ENDOTHELIN | FLOW VELOCITY | REFRACTORY PROSTATE-CANCER | MESSENGER-RNA | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | ESSENTIAL-HYPERTENSION | EX-VIVO | HEMATOLOGY | HUMAN ARTERIES | Endothelin-1 - antagonists & inhibitors | Follow-Up Studies | Humans | Middle Aged | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Endothelium, Vascular - drug effects | Male | Microcirculation - drug effects | Enzyme Inhibitors - administration & dosage | Heart Rate - drug effects | Adult | Female | Blood Pressure - drug effects | Uric Acid - blood | Lipoprotein(a) - blood | Kidney - drug effects | Coronary Artery Disease - metabolism | Coronary Artery Disease - drug therapy | Blood Glucose - drug effects | omega-N-Methylarginine - administration & dosage | Endothelium, Vascular - metabolism | Triglycerides - blood | Receptor, Endothelin A - metabolism | Coronary Circulation - drug effects | Nitric Oxide - metabolism | Antagonists (Biochemistry) | Endothelin | Patient outcomes | Atherosclerosis | Dosage and administration | Drug therapy | Health aspects | endothelium independent coronary flow reserve | endothelin-1 (ET-1) | coronary artery diameter | Atrasentan | endothelium dependent coronary blood flow
Journal Article
European Urology, ISSN 0302-2838, 2008, Volume 55, Issue 5, pp. 1112 - 1123
Abstract Background The endothelin-A receptor (ETAR) has been implicated in the progression of prostate cancer. Objectives To investigate the safety and... 
Urology | Endothelin-A receptor ZD4054 | Castration-resistant prostate cancer | Hormone-resistant prostate cancer | Bone metastasis | SURVIVAL | ATRASENTAN | HEART-FAILURE | GUIDELINES | Endothelin-A receptor | DOCETAXEL | ZD4054 | MEN | UROLOGY & NEPHROLOGY | PROGRESSION | Bone Neoplasms - mortality | Prognosis | Prospective Studies | Humans | Middle Aged | Bone Neoplasms - secondary | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Drug Resistance, Neoplasm | Male | Dose-Response Relationship, Drug | Endothelin A Receptor Antagonists | Aged, 80 and over | Bone Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Prostatic Neoplasms - surgery | Risk Assessment | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Receptor, Endothelin A - administration & dosage | Probability | Treatment Outcome | Bone Neoplasms - surgery | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Maximum Tolerated Dose | Survival Analysis | Aged | Neoplasm Staging | Pain Measurement | Adenocarcinoma - mortality | Adenocarcinoma - surgery | Clinical trials | Care and treatment | Cancer patients | Metastasis | Prostate cancer | Endothelin | Analysis | Hormones | Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2012, Volume 23, Issue 3, pp. 688 - 694
Journal Article
Cancer, ISSN 0008-543X, 11/2008, Volume 113, Issue 9, pp. 2478 - 2487
Journal Article
Journal of Hypertension, ISSN 0263-6352, 02/2017, Volume 35, Issue 2, pp. 376 - 384
OBJECTIVE:Arterial stiffness and calcification are nontraditional cardiovascular risk factors in chronic kidney disease (CKD). Using a rat model of CKD with... 
Endothelin | Inflammatory cytokines | Arterial stiffness | S100A8/S100A9 | Vascular calcification | Chronic kidney disease | Atrasentan | Endothelin type A receptor | arterial stiffness | ERYTHROPOIETIN-INDUCED HYPERTENSION | chronic kidney disease | vascular calcification | UREMIC RATS | NECROSIS-FACTOR-ALPHA | inflammatory cytokines | AORTIC STIFFNESS | BLOOD-PRESSURE | endothelin | endothelin type A receptor | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | STAGE RENAL-DISEASE | CARDIOVASCULAR RISK | atrasentan | GLYCATION END-PRODUCTS | Tumor Necrosis Factor-alpha - metabolism | Calgranulin B - metabolism | Pulse Wave Analysis | Rats, Wistar | Calgranulin A - metabolism | Calcium - administration & dosage | Male | Renal Insufficiency, Chronic - complications | Macrophages | Pyrrolidines - pharmacology | Inflammation - complications | Interleukin-1beta - metabolism | Phosphorus, Dietary - administration & dosage | Vascular Calcification - complications | Vascular Calcification - physiopathology | Vitamin D - administration & dosage | Blood Pressure - drug effects | Vascular Stiffness | Interleukin-6 - metabolism | Aorta, Thoracic - pathology | Biomarkers - metabolism | Endothelin A Receptor Antagonists - pharmacology | Endothelin-1 - metabolism | Aorta, Thoracic - metabolism | Rats | Vascular Calcification - prevention & control | Receptor, Endothelin A - drug effects | Renal Insufficiency, Chronic - physiopathology | Animals | Inflammation - prevention & control | Inflammation - physiopathology
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2019 - 2022
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium... 
pharmacokinetics | endothelin receptor antagonist | dose‐finding | pharmacodynamics | diabetic nephropathy | dose-finding | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | AVOSENTAN | Biomarkers - urine | Humans | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Diabetic Nephropathies - blood | Sodium - metabolism | Dose-Response Relationship, Drug | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Endothelin A Receptor Antagonists - adverse effects | Renal Insufficiency - complications | Renal Insufficiency - drug therapy | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Severity of Illness Index | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Endothelin A Receptor Antagonists - pharmacokinetics | Biological Variation, Population | Renal Elimination - drug effects | Renal Insufficiency - metabolism | Albuminuria - prevention & control | Atrasentan - therapeutic use | Metabolic Clearance Rate - drug effects | Atrasentan - administration & dosage | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Atrasentan - pharmacokinetics | Type 2 diabetes | Antimitotic agents | Medical research | Evaluation | Endothelin | Analysis | Diabetic nephropathies | Albumin | Medicine, Experimental | Antineoplastic agents | Creatinine | Kidneys | Sodium | Diabetes mellitus (non-insulin dependent) | Diabetes mellitus | Brief Reports | Brief Report
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2007, Volume 110, Issue 9, pp. 1959 - 1966
BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in... 
time to disease progression, bone metastasis | endothelin‐A receptor antagonist | hormone‐refractory prostate cancer | atrasentan | Bone metastasis | Hormone-refractory prostate cancer | Time to disease progression | Atrasentan | Endothelin-A receptor antagonist | OVARIAN-CARCINOMA CELLS | MITOXANTRONE | bone metastasis | OSTEOBLASTIC BONE METASTASES | endothelin-A receptor antagonist | time to disease progression | HEART-FAILURE | RECEPTOR ANTAGONIST | PHARMACOKINETICS | ONCOLOGY | CLINICAL-TRIALS | ENDOTHELIN-1 | hormone-refractory prostate cancer | EXPRESSION | PROGRESSION | Prostatic Neoplasms - pathology | Adenocarcinoma - pathology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Bone Neoplasms - secondary | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Alkaline Phosphatase - drug effects | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Pyrrolidines - therapeutic use | Aged, 80 and over | Prostate-Specific Antigen - drug effects | Aged | Bone Neoplasms - drug therapy | Alkaline Phosphatase - blood | Prostatic Neoplasms - drug therapy | Adenocarcinoma - mortality | Antimitotic agents | Complications and side effects | Endothelin | Physiological aspects | Clinical trials | Reports | Dosage and administration | Research | Drug therapy | Antineoplastic agents | Prostate cancer | Clinical Medicine | prostate cancer | hormone-refractory | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Journal Article
Journal Article